Entergy

Entergy Operations, Inc.
1448 S.R. 333
Russellville, AR 72802
Tel 501 858 5000

0CAN110501

November 7, 2005

U.S. Nuclear Regulatory Commission
Attn: Document Control Desk
Washington, DC 20555-0001

Subject: Drug Testing Laboratory Performance Report
Arkansas Nuclear One – Units 1 and 2
Docket Nos. 50-313 and 50-368
License Nos. DPR-51 and NPF-6

Dear Sir or Madam:

As part of the routine blind performance drug testing program, Arkansas Nuclear One (ANO) sent two blind samples with an HHS certified concentration of PCP to Northwest Toxicology/Lab One along with other certified samples on August 30, 2005. On August 31, 2005, Northwest Toxicology/Lab One reported to ANO that all samples of the subject lot tested negative. Upon receipt of this information, ANO began an investigation of the incident.

On September 6, 2005, Northwest/Toxicology Lab One was notified of the discrepancy and was requested to conduct an investigation into the cause of the error. The laboratory reported that the samples were retested and were found to contain 23 ng/ml of PCP, below the cutoff level of 25 ng/ml. Therefore, these specimens were not reported as positive.

During the investigation of the incident, the supplier of the certified samples reported that another of their clients had experienced similar problems with samples from the same lot number as ANO's problem samples. Subsequently, the supplier had samples from the suspect lot retested by an independent lab with satisfactory results.

The supplier noted that at the time the subject samples were shipped to ANO and the other client that experienced problems, extremely hot temperatures existed in the mid-west. The supplier concluded that these high temperatures were the likely cause of the sample degradation.

A022

In accordance with paragraph 2.8(e)(4) of Appendix "A" to 10CFR26, enclosed is the investigation report provided to ANO by Northwest Toxicology/Lab One concerning the unsatisfactory performance test result.

There are no commitments contained in this submittal.

Sincerely,

Dale E. James
Manager, Licensing
DEJ/rhs

cc: Dr. Bruce S. Mallett
Regional Administrator
U. S. Nuclear Regulatory Commission
Region IV
611 Ryan Plaza Drive, Suite 400
Arlington, TX 76011-8064

NRC Senior Resident Inspector
Arkansas Nuclear One
P.O. Box 310
London, AR 72847

U. S. Nuclear Regulatory Commission
Attn: Mr. Drew Holland
Mail Stop 0-7 D1
Washington, DC 20555-0001

Attachment
to
0CAN110501

Vendor Quality Assurance Report

QUALITY ASSURANCE REPORT

Client: **Entergy/ENT0100C**
ANO
Subject: **Blind QC Failure**
Specimen ID #s: **E10414525/E10414531**
Lab Accession#s: **4255027/4255061**

BACKGROUND:

Northwest Toxicology/Lab*O*ne was notified by Steve Kaufmann of Entergy on 9/06/05 that the specimens identified above were submitted as a blind quality control samples and the reported negative results were not consistent with the expected results. These specimens were known to contain PCP at a target concentration of 39 ng/mL.
The details of the issue were forwarded to Laurie Tobler, Director of Quality Improvement for investigation and follow-up documentation.

INVESTIGATION:

Determining cause of the error:

1. Specimens E10414525(LAN4255027) and E10414531(LAN4255061) were received at the laboratory on 8/31/05. These specimens were analyzed by immunoassay (KIMS) and found to be negative. These results were certified and reported on 9/01/05.
2. On 9/13/05, the Laboratory was requested to perform an LOD PCP confirmation by GCMS on these specimens in order to determine the concentration of PCP in them. On 9/20/05, both specimens were found to contain 23 ng/mL of PCP by GC/MS.

DISCUSSION/SUMMARY OF FINDINGS:

We have concluded that the discrepancy between the reported and expected results were due to an insufficient concentration of PCP submitted in the blind quality control specimens identified above. The initial test cutoff for PCP is 25 ng/mL; therefore, specimens that contain 23 ng/mL would not be identified/reported as positive.

Prepared by:

Laurie Tobler
Director of Quality Improvement

Date:

9-27-05
September 27, 2005

Reviewed by:

David J. Kuntz, Ph.D.,
Laboratory Director

Date:

10/25/05
October 25, 2005

cc: Raffie S. Bezdjian, Director of Operations
David J. Kuntz, Ph.D., Laboratory Director
Todd Bjorklund, Client Service Manager